Integrative Research Laboratories AB — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications1liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
IRL757This clinical trial's goal is to evaluate if the IRL757 is safe and has a good tolerability in participants with Parkinson's disease and experiencing apathy (a lack of interest or motivation). In addition, the trial is aiming to learn if IRL757 has effects on the symptoms of Parkinson's disease. Researchers will compare the effects of IRL757 to a placebo (a look-alike substance that contains no drug). Participants who fit the study criteria will be treated with the study drug (either the active drug IRL757 or placebo) for 12 weeks and will visit the clinic at 5 defined timepoints for check-ups and tests. A follow-up call after the end of treatment will be done 4 weeks after the last study drug intake.	Parkinson	Phase 1/2	Traitement symptomatique	Bulgaria, Germany, Poland, Spain	À vérifier
PirepematThis is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.	Parkinson	Phase 2	À vérifier	France, Germany, Netherlands, Poland, Spain, Sweden	À vérifier
PirepematThis is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.	Parkinson	Phase 2	À vérifier	France, Germany, Netherlands, Poland, Spain, Sweden	À vérifier
IRL757This clinical trial's goal is to evaluate if the IRL757 is safe and has a good tolerability in participants with Parkinson's disease and experiencing apathy (a lack of interest or motivation). In addition, the trial is aiming to learn if IRL757 has effects on the symptoms of Parkinson's disease. Researchers will compare the effects of IRL757 to a placebo (a look-alike substance that contains no drug). Participants who fit the study criteria will be treated with the study drug (either the active drug IRL757 or placebo) for 12 weeks and will visit the clinic at 5 defined timepoints for check-ups and tests. A follow-up call after the end of treatment will be done 4 weeks after the last study drug intake.	Parkinson	Phase 1/2	Traitement symptomatique	Bulgaria, Germany, Poland, Spain	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
IRL757	Parkinson	Phase 1/2	NCT07461220	LIFT-PD — Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy	RECRUITING
Pirepemat	Parkinson	Phase 2	NCT05258071	A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)	COMPLETED

Publications

1

Molécule	Indication / population	Titre	Journal	Date
Pirepemat		First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers.	Clinical pharmacology in drug development